Objective To analyze the effect of donepezil hydrochloride combined with memantine on cognitive function in patients with Alzheimer's disease(AD).Methods A randomized controlled trial was conducted among 90 patients with AD who were treated at the Zaozhuang Mental Health Center from January 2021 to March 2023.The patients were divided into a donepezil group and a combination group using a random number table grouping method,with 45 patients in each group.The donepezil hydrochloride group received only oral administration of donepezil hydrochloride tablets,while the combination group received oral administration of both donepezil hydrochloride tablets and memantine tablets.The two groups were continuously treated for 12 weeks.Before and after treatment,the Activities of Daily Living scale(ADL)score,the Behavioral Pathology in Alzheimer's Disease Rating Scale(BEHAVE-AD)score,the Mini-Mental State Scale(MMSE)score,and biochemical indicators(homocysteine,neuron-specific enolase,and S100β)were compared between the two groups.Adverse drug reactions were observed in each group.Results After treatment,the ADL,BEHAVE-AD,and MMSE scores in the combination group were(78.9±6.1)points,(5.2±0.5)points,and(22.8±2.2)points,respectively,and they were(65.2±5.9)points,(9.6±0.9)points,and(19.4±2.4)points,respectively,in the donepezil hydrochloride group.The ADL and MMSE scores in the combination group were significantly higher than those in the donepezil hydrochloride group(t=10.83,7.01,both P＜0.001).The BEHAVE-AD score in the combination group was significantly lower than that in the donepezil hydrochloride group(t=-28.67,P＜0.001).After treatment,serum levels of homocysteine,neuron-specific enolase,and S100β in the combination group were(17.8±3.6)μmol/L,(16.8±2.7)μg/L,and(17.4±7.5)μg/L,respectively,which were significantly lower than(21.5±3.3)μmol/L,(20.4±3.7)μg/L,and(23.5± 5.1)μg/L in the donepezil hydrochloride group(t=-5.08,-5.27,-4.51,all P＜0.001).The incidence of adverse drug reactions in the combination group was 13.3％(6/45),which was slightly,but not significantly,higher than 8.9％(4/45)in the donepezil group(x2=0.45,P=0.502).Conclusion The combination of donepezil hydrochloride and memantine can effectively improve the mental and behavioral symptoms and cognitive function of patients with AD,improve daily living ability,and do not increase adverse reactions.The combined therapy has high clinical application value.
Alzheimer diseaseDrug therapy,combinationCognitive dysfunctionPsychomotor performanceActivities of daily livingCysteinePhosphopyruvate hydrataseS100 ProteinsDonepezilMemantine
NETL
NSTL
万方数据
维普
